Embecta (EMBC) vs Avita Medical (RCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Avita Medical (RCEL) has outperformed Embecta (EMBC) over the past year, gaining 138.6% versus a loss of 57.1%. Avita Medical is the larger company by market cap ($394.0 million vs $325.8 million), about 1.2 times the size. Embecta pays a dividend yielding 8.00%, while Avita Medical does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EMBC | RCEL |
|---|---|---|
| Share price | $5.75 | $12.74 |
| Market cap | $325.79M | $394.01M |
| 1-day change | -2.71% | -2.37% |
| YTD return | -50.25% | +278.26% |
| 1-year return | -57.11% | +138.57% |
| 5-year return | — | -24.87% |
| P/E ratio (TTM) | 3.91 | — |
| Forward P/E | 3.26 | — |
| EPS (TTM) | $1.47 | $-1.43 |
| Dividend yield | 8.00% | 0.00% |
| Annual dividend | $0.46 | $0.00 |
| 52-week high | $14.91 | $13.50 |
| 52-week low | $2.77 | $3.22 |
| Distance from 52-week high | -61.44% | -5.63% |
| Analyst consensus | none | none |
| Avg. price target upside | -30.43% | -5.57% |
| Average volume | 1.37M | 441.70K |
| Shares outstanding | 56.66M | 30.93M |
| Employees | 1,850 | 226 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RCEL has outperformed EMBC by 195.7 percentage points over the past year.
- Embecta offers a meaningfully higher dividend yield (8.00% vs 0.00%).
About Embecta
EMBC stock →Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Health Care · Medical/Dental Instruments · 1,850 employees
About Avita Medical
RCEL stock →AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions.
Health Care · Medical/Dental Instruments · 226 employees
EMBC vs RCEL FAQ
Which is bigger, Embecta or Avita Medical?
Avita Medical (RCEL) is larger, with a market capitalization of $394.01M compared with $325.79M for Embecta (EMBC).
Which stock has performed better over the past year, EMBC or RCEL?
RCEL returned +138.57% over the past 12 months, compared with -57.11% for EMBC (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Embecta or Avita Medical?
Embecta pays a dividend yielding 8.00%, while Avita Medical does not currently pay a regular dividend.
Are Embecta and Avita Medical in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.